To hear about similar clinical trials, please enter your email below
Trial Title:
DAratumumab and REvlimid REfractory MM
NCT ID:
NCT06541860
Condition:
Multiple Myeloma
Conditions: Official terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Other
Summary:
Retrospective and prospective multicenter observational study on patients with relapsed
and refractory multiple myeloma after anti-CD38 MoAb therapy and IMIDS treated with
onlabel regimens.
Criteria for eligibility:
Study pop:
Patients with relapsed and refractory multiple myeloma after anti-CD38 MoAb therapy and
IMIDS treated with onlabel regimens.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
Phase I
- Patients with RRMM after therapy with anti-CD38 MoAb plus IMIDS started on therapy
with PVD scheme
- Patients aged ≥ 18 years
- Patients able to understand and voluntarily sign an informed consent and be willing
to consent to the review of clinical data
Phase II
- Patients with RRMM after first-line therapy with anti-CD38 MoAb plus IMIDS started
on therapy with on-label schemes
- Patients aged ≥ 18 years
- Patients able to understand and voluntarily sign an informed consent and be willing
to consent to the review of clinical data
Exclusion Criteria:
- Patients not willing to consent to review of clinical data
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Irccs San Matteo Pavia
Address:
City:
Pavia
Zip:
27100
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Alessandra Ferrari
Phone:
0382.503689
Email:
alessandra.ferrari@smatteo.pv.it
Investigator:
Last name:
Silvia Mangiacavalli
Email:
Principal Investigator
Start date:
August 21, 2023
Completion date:
August 21, 2028
Lead sponsor:
Agency:
Fondazione IRCCS Policlinico San Matteo di Pavia
Agency class:
Other
Source:
Fondazione IRCCS Policlinico San Matteo di Pavia
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06541860
